Polycystic Kidney Disease Drugs Market size was valued at USD 481.22 Million in 2023 and is anticipated to exceed USD 1.11 Billion by the end of 2036, registering over 6.7% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of polycystic kidney disease drugs is evaluated at USD 510.24 Million. The growth of the market can be attributed to the worldwide increasing incidence of chronic kidney diseases, resulting in death and serious medical issues. In accordance with the Centers for Disease Control and Prevention, a total of 37 million Americans are estimated to have chronic kidney disease, which is 15% of the region's population. Further, the growing prevalence of hypertension, and surging research and development activities for the development of chronic kidney disease drugs are some further factors that are anticipated to massively drive the market’s growth further over the projected time frame.
In addition to these, factors that are believed to fuel the market growth of polycystic kidney disease drugs include the rise in PKD drug trials, followed by the growth in the approval of novel drugs by the government, along with the development of a wide range of medications by key players are anticipated to expand the global polycystic kidney disease drugs market size during the forecast period. For instance, Reata Pharmaceuticals, Inc. announced positive phase II results for bardoxolone methyl in chronic renal disease caused by Alport syndrome and autosomal dominant polycystic kidney disease in July 2018. Additionally, growing awareness about kidney diseases among people is also predicted to present the potential for market expansion over the projected period.
Growth Drivers
The Surge in the Incidence of Autosomal Dominant Polycystic Kidney Diseases (ADPKD) - ADPKD is a rare condition, as it contributes significantly to chronic kidney disease and kidney failure. In addition, polycystic kidney disease, the most common chronic kidney disease, substantially increases the prevalence of chronic kidney disease. As a result, an increasing prevalence of ADPKD is expected to drive global polycystic kidney disease drugs market growth over the forecast period. For instance, around 200,000 to 500,000 people in the United States and another 13,000,000 people around the world suffer from ADPKD, and only about 25% of the population is aware of the disease.
Growing Initiatives to Raise Awareness About PKDs - For instance, PKD Foundation is the only non-profit in the U.S. exclusively dedicated to treating and curing polycystic kidney disease. Over 1,300 research studies were funded and USD 1.5 billion in research funding has been leveraged.
Increasing Healthcare Spending Worldwide - According to the Centers for Medicare & Medicaid Services, the United States spent USD 4.1 trillion on healthcare services in 2020, representing 19.7% of the GDP.
Rising Number of Research and Development Activities - According to the World Bank, the number of researchers in R&D activities has increased from 14,12 researchers per million in 2015 to 1,597 researchers per million in 2018.
Growth in Personal Disposable Income - According to the Bureau of Economic Analysis, in the United States, personal income increased by USD 47.0 billion (0.2%) in July 2020, and disposable personal income expanded by USD 37.6 billion (0.2%).
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
6.7% |
|
Base Year Market Size (2023) |
USD 481.22 Million |
|
Forecast Year Market Size (2036) |
USD 1.11 Billion |
|
Regional Scope |
|
Type {Autosomal Dominant Polycystic Kidney Disease (ADPKD), Autosomal Recessive Polycystic Kidney Disease (ARPKD)}
The global polycystic kidney disease drugs market is segmented and analyzed for demand and supply by type into autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), and others. Out of the three types of segments, the autosomal dominant polycystic kidney disease (ADPKD) segment is anticipated to capture the largest market size in the global polycystic kidney disease drugs market over the projected time frame. The growth of the segment can be attributed to the worldwide increasing incidence of autosomal dominant polycystic kidney diseases. For instance, it was observed that the prevalence of ADPKD is estimated to be somewhere between 1 in 500-1,000 among the general population. Each year, about 5,900 new cases are recorded in the United States. Besides this, escalating approval of the novel drugs is also anticipated to propel the segment growth over the projected time frame.
End-user (Hospitals, Specialty Clinics)
The global polycystic kidney disease drugs market is also segmented and analyzed for demand and supply by the end user into hospitals, specialty clinics, and others. Amongst these three segments, the hospitals segment is expected to garner a significant share owing to the fact that patients suffering from polycystic kidney disease often visit hospitals for treatments such as hemodialysis and peritoneal dialysis. Therefore, an increase in the PKD patient pool is anticipated to fuel the segment growth, along with the adequacy of favorable reimbursement policies in developed nations, is estimated to drive the growth of the segment over the forecast period. On the other hand, the specialty clinics segment is projected to witness a notable CAGR during the forecast period, owing to the rising awareness of this disease amongst people across the globe. The growing inclination of patients towards early diagnosis and treatment of polycystic kidney disease is also propelling the demand for quality treatment. This, as a result, is projected to generate numerous opportunities for the growth of the segment in the coming years.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Treatment |
|
|
By Diagnosis |
|
|
By End User |
|
North American Market Forecast
The North America polycystic kidney disease drugs market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2036. The growth of the market can be attributed majorly to the rise in per capita income, along with rising awareness of the early diagnosis of chronic kidney diseases as of the advancement in the medical array in the region. In accordance with data provided by the World Bank, the annual income of each individual in the United States rose by USD 69287.5 in 2021 from USD 63027.7 in the year 2020. Further, the presence of affordable healthcare policies in the region, along with intensive drug research and development, is also anticipated to contribute to the market growth in the region. In addition, a significant increase in the medical and healthcare industries, easy drug accessibility, and dynamic surge in dialysis procedures are further expected to fuel the global polycystic kidney disease drugs market in the region during the forecast period.
APAC Market Statistics
Furthermore, the Asia Pacific polycystic kidney disease drugs market is anticipated to display notable market growth by the end of 2036. The growth of the market can be attributed to the mounting proportion of chronic kidney disorders, coupled with the developing healthcare facilities in emerging nations such as China, India, and so on. For instance, in 2019, there were around 9 million new cases and nearly 783 035 fatalities owing to CKD in the Asia Pacific region. Between 1990 and 2019, the region's CKD prevalence more than doubled, rising from around 203.8 million to 433.6 million. In addition to this, the increasing initiatives by the government of nations to raise awareness about chronic kidney disorders, along with the escalating ratio of aging people, are some further factors that are anticipated to propel the market growth throughout the projected time frame in the region.
XORTX Therapeutics Inc. declared the positive outcomes from XRX-OXY-101 (“PK Clinical Trial”). The outcomes showed an increase in oral bioavailability for two versions compared to a control formulation in advance of ADPKD's late-stage phase 3 registration trial.
Pano Therapeutics, Inc. has acquired the privately-held NovaTarg Therapeutics, Inc. to strengthen Pano Therapeutic Inc’s drug discovery and development capabilities and enhance its portfolio.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?